ClinicalTrials.gg
RecruitingNCT06038578Updated Oct 8, 2026

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

A Phase 2 interventional study of TRK-950 and Ramucirumab in Gastric Adenocarcinoma, Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Toray Industries, Inc. Recruiting at 27 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Toray Industries, Inc · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 805 studies in Stomach Neoplasms with a site in United States — 157 open to participants now, 239 under way, 12 of them phase 3. Stomach Neoplasms · United States.

Planned enrollment
168th of 687
146 · median 53
Started
2023
with 32 others
Phase 2
223 of 805
27 open now
Primary completion
2027-10
later than 121 of 238 live
Registered
681st of 805
by date

Among the 805 studies in Stomach Neoplasms with a site in United States, this one is the 168th largest by planned enrollment of the 687 interventional ones that give a count, is one of 33 that started in 2023, is one of 223 in phase 2, reaches primary completion later than 121 of the 238 other live ones, and was the 681st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

157 of the 805 studies in Stomach Neoplasms with a site in United States are open now. Recruiting first, the newest first:

152 more — sign in →

All 157 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 805 studies in Stomach Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.

Read the detailed description

This study will assess and compare the efficacy, safety, pharmacokinetics (PK), optimal dose and anti-drug antibodies (ADA) and neutralizing antibodies (NAbs) development of TRK-950 at two separate dose levels in combination with RAM + PTX as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma. The primary objective is progression free survival (PFS). Secondary objectives are overall survival, objective response rate, best overall response, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity of TRK-950 when used in combination with RAM+PTX.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Keywords

  • Gastric Cancer, Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • TRK-950
  • CAPRIN-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed , or locally advanced and unresectable gastric or GEJ adenocarcinoma.
  • The patient is eligible to receive Ramucirumab + Paclitaxel.
  • Documented objective radiographic or clinical disease progression (e.g., any new or worsening malignant effusion documented by ultrasound examination) which may be confirmed by pathologic criteria (histology and/or cytology) if appropriate, during or after treatment. The prior treatment must meet one of the following criteria with the following treatment history:

    1. First treatment for metastatic disease or locally advanced disease without experiencing / neo-adjuvant treatment, which progressed during treatment or within 4 months after the last dose of treatment
    2. Adjuvant / neo-adjuvant treatment which progressed more than 6 months after the last dose of treatment and first treatment for metastatic disease or locally advanced disease, which progressed during the treatment or within 4 months after the last dose of treatment
    3. Adjuvant / neo-adjuvant treatment which progressed during treatment or within 6 months after the last dose of treatment
    4. Adjuvant / neo-adjuvant treatment which progressed during treatment or within 6 months after the last dose of treatment and first treatment for metastatic disease or locally advanced disease, which progressed during treatment or within 4 months after the last dose of treatment
  • Presence of primary or metastatic disease, measurable per v1.1 on CT scan.
  • (ECOG) Performance Status of 0 or 1.
  • of at least 3 months.
  • Age ≥ 18 years in the US and Japan, and ≥ 19 years of age in Korea.
  • Signed, written IRB-approved .
  • Adequate organ function from specimens collected within 14 days prior to Day 1.
  • For men and women of child-producing potential, the use of effective methods during the study and for 6 months after the last dose of TRK-950.
  • All patients must sign a pre-screening consent to assess tumor tissue to determine eligibility. Tumor tissue must be evaluable for CAPRIN-1 staining at a CLIA certified laboratory and meet or exceed the cutoff value (30% at ≥ 2+ staining) as defined in the expression level requirements.

Exclusion criteria

Exclusion Criteria:

  • Prior history of treatment with ramucirumab or paclitaxel.
  • positive gastric or GEJ adenocarcinoma.
  • Major surgery within 28 days prior to randomization.
  • Baseline (QTc) interval of > 470 msec for females and > 450 msec for males calculated using Fridericia's formula.
  • (NYHA) Class II - IV symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia.
  • The patient has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or , within 3 months prior to randomization.
  • The patient has a history of (non-infectious) pneumonitis that required or has current pneumonitis.
  • Clinically symptomatic venous thromboembolism or current treatment with anti-coagulants. (Patients receiving prophylactic and low-dose anticoagulation therapy are eligible provided that the coagulation parameter defined in the Inclusion Criterion 9 is met.)
  • Uncontrolled arterial hypertension ≥ 150 mmHg (systolic) or ≥ 90 mmHg (diastolic) despite standard medical management.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  • Pregnant or nursing women.
  • Treatment with radiation therapy within 2 weeks, or treatment with chemotherapy, immunotherapy, targeted therapy, or therapy within 4 weeks prior to randomization (within 2 weeks for Oral FU (S1 and capecitabine)).
  • The patient has significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within 3 months prior to randomization.
  • ascites, paracentesis in the last 3 months, or undergoes regular paracentesis procedures.
  • History of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
  • The patient has a serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to randomization.
  • The patient has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (e.g., hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
  • Known active infection with , or . Patients with a history of hepatitis B or C are allowed if HBV DNA or Hep C RNA are undetectable.
  • The patient is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. Patients who have recently discontinued dosing of study drug are eligible to participate as long as the final dose of study drug was ≥ 28 days from randomization for participation in this study. Patients participating in surveys or observational studies are eligible to participate in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Arm A: TRK-950(5 mg/kg)+Ramucirumab+Paclitaxel

    Participants who will be randomized to receive a 5 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.

    Biological: TRK-950 · Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Arm B: TRK-950(10 mg/kg)+Ramucirumab+Paclitaxel

    Participants who will be randomized to receive a 10 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.

    Biological: TRK-950 · Drug: Ramucirumab · Drug: Paclitaxel

  • Active comparator
    Arm C: Ramucirumab+Paclitaxel

    Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.

    Drug: Ramucirumab · Drug: Paclitaxel

Interventions

  • BiologicalTRK-950

    5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle

  • 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle

    Also known as: CYRAMZA®

  • 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle

06

What researchers measure

Primary outcomes

  1. Progression free Survival (PFS)

    Progression free Survival (PFS) is defined as time from the date of randomization to the date of progressive disease or death due to any cause based on Independent Central Review.

    Time frame: Time from date of randomization to the date of progressive disease or death due to any cause, whichever occurs first, up to approximately 24 months

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Time from the date of randomization to the date of death due to any cause, up to approximately 24 months

  2. Objective response rate (ORR)

    Objective response rate (ORR) is defined as the proportion of participants who achieve a best overall response of complete response (CR) or partial response (PR) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by Independent Central Review.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  3. Progression free Survival (PFS)

    Progression free Survival (PFS) is defined as time from the date of randomization to the date of progressive disease or death due to any cause based on investigator assessment.

    Time frame: Time from date of randomization to the date of progressive disease or death due to any cause, whichever occurs first, up to approximately 24 months

  4. Objective response rate (ORR)

    Objective response rate (ORR) is defined as the proportion of participants who achieve a best overall response of complete response (CR) or partial response (PR) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by investigator.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  5. Best overall response (BOR)

    The best overall response is defined as the best overall response (BOR) recorded from the start of treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by Independent Central Review based.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  6. Best overall response (BOR)

    The best overall response is defined as the best overall response (BOR) recorded from the start of treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by investigator.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  7. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the proportion of participants who achieve a best overall response of complete response (CR), partial response (PR) or stable disease (SD) for a minimum of 6 weeks using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by Independent Central Review based.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  8. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the proportion of participants who achieve a best overall response of complete response (CR), partial response (PR) or stable disease (SD) for a minimum of 6 weeks using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by investigator.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 24 months

  9. Duration of response (DoR)

    Duration of response (DoR) is defined as the time from the initial response (CR or PR) until documented tumor progression or death from any cause based on Independent Central Review based.

    Time frame: Time from initial response (CR or PR) to date of documented disease progression or death due to any cause, whichever occurs first, up to approximately 24 months

  10. Duration of response (DoR)

    Duration of response (DoR) is defined as the time from the initial response (CR or PR) until documented tumor progression or death from any cause based on investigator assessment.

    Time frame: Time from initial response (CR or PR) to date of documented disease progression or death due to any cause, whichever occurs first, up to approximately 24 months

  11. Incidence of Treatment-emergent Adverse Events (TEAE)

    Adverse events will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: From time subjects are enrolled up to 45 days after last study dose

  12. Serious Adverse Events (SAEs)

    Adverse events will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: From time subjects are enrolled up to 45 days after last study dose

  13. Adverse Events of Special Interest (AESI)

    Adverse events will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: From time subjects are enrolled up to 45 days after last study dose

  14. Incidence of Discontinuation due to AE

    Adverse events will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: From time subjects are enrolled up to 45 days after last study dose

  15. Incidence of Physical Examination Findings, Vital sign measurements, Standard clinical laboratory parameters, ECG parameters

    Time frame: From time subjects signs informed consent form up to 45 days after last study dose

  16. Pharmacokinetic Parameter of Concentration of drug at the end of infusion (CEOI) of TRK-950

    Time frame: Cycle 1 on day 1 and 15, subsequent cycles on day 1 (each cycle is 28 days)

  17. Pharmacokinetic Parameter of Trough Serum Concentration (Ctrough) of TRK-950

    Time frame: Cycle 1 on day 1 and 15, subsequent cycles on day 1 (each cycle is 28 days)

  18. Pharmacokinetic Parameter of Area Under the Curve (AUC) of TRK-950

    Time frame: Cycle 1 on day 1 and 15, subsequent cycles on day 1 (each cycle is 28 days)

  19. Pharmacokinetic Parameter of Concentration of drug at the end of infusion (CEOI) of Ramucirumab

    Time frame: Cycle 1 and 4 on day 1 and 15, Cycles 2, 3 and subsequent cycles on day 1 (each cycle is 28 days)

  20. Pharmacokinetic Parameter of Trough Serum Concentration (Ctrough) of Ramucirumab

    Time frame: Cycle 1 and 4 on day 1 and 15, Cycles 2, 3 and subsequent cycles on day 1 (each cycle is 28 days)

  21. Pharmacokinetic Parameter of Area Under the Curve (AUC) of Ramucirumab

    Time frame: Cycle 1 and 4 on day 1 and 15, Cycles 2, 3 and subsequent cycles on day 1 (each cycle is 28 days)

  22. Pharmacokinetic Parameter of Concentration of drug at the end of infusion (CEOI) of Paclitaxel

    Time frame: Cycle 1 and 4 on day 1 and 15 (each cycle is 28 days)

  23. Pharmacokinetic Parameter of Trough Serum Concentration (Ctrough) of Paclitaxel

    Time frame: Cycle 1 and 4 on day 1 and 15 (each cycle is 28 days)

  24. Pharmacokinetic Parameter of Area Under the Curve (AUC) of Paclitaxel

    Time frame: Cycle 1 and 4 on day 1 and 15 (each cycle is 28 days)

  25. Percentage of participants who are Anti-drug antibody (ADA)-Positive and Neutralizing antibodies (NAbs)

    Time frame: Cycle 1 on day 1 and 15, subsequent cycles on day 1 (each cycle is 28 days)

  26. Change from Baseline in Patient Reported Quality of Life assessed by the Questionnaire - Core questionnaire EORTC QLQ-C30 scores

    The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life for cancer patients. It incorporates five functional scale (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: From Cycle 1 on day 1 through study completion, up to approximately 24 months (each cycle is 28days)

  27. Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores

    The EQ-5D questionnaire consists of the following five dimensions, each describing a different aspect of health: Mobility, Self-Care, Usual Activities, Pain/Discomfort and Anxiety/ Depression. The participants self-assess each dimension has three response levels of severity: no problems, some problems, extreme problems.

    Time frame: From Cycle 1 on day 1 through study completion, up to approximately 24 months (each cycle is 28days)

07

Study locations

27 of 27 sites recruiting
08

References and documents

Publications

  • Koyama T, Yonemori K, Sato J, Katsuya Y, Okada M, Yoshida T, Okano F, Yamamoto N. A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. Invest New Drugs. 2026 Apr 14. doi: 10.1007/s10637-026-01609-z. Online ahead of print. PubMed 41979863 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 48 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 48 months is above that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jun 2026 → Oct 2027 and completion Jun 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 15, 2023
StartActual
Oct 4, 2023
Primary completionEst.
Oct 31, 2027was Jun 2026
CompletionEst.
Oct 31, 2027was Jun 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Oct 31, 2027
Oct 8, 2026
Study completion
Jun 30, 2026→Oct 31, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Jun 30, 2026→Oct 31, 2027
    Study completion Jun 30, 2026→Oct 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06038578
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Oct 4, 2023
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

(Asia sites)Toray Contact for Clinical Trial Information
Contact
npdd-clinical.toray.mb@mail.toray
+81 467-32-9948
(US sites) Contact for Clinical Trial Information
Contact
lmullins@td2inc.com
954-612-8596

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK-950

Start the discussion